SCHEMBL30294307

SCHEMBL30294307

COc1cc(F)ccc1Nc1cc(F)c(F)cc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.52
APAF1 O14727 1/20 0.52
RECQL P46063 1/20 0.52
CASP6 P55212 1/20 0.52
CACNA1B Q00975 1/20 0.52
APBA1 Q02410 1/20 0.52
MCL1 Q07820 1/20 0.52
CASP8 Q14790 1/20 0.52
AKR1C3 P42330 2/20 0.52
AKR1C2 P52895 2/20 0.52
CTSV O60911 2/20 0.52
CTSL P07711 2/20 0.52
DHODH Q02127 1/20 0.47
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
PYGL P06737 3/20 0.44
CDC25B P30305 1/20 0.44
JAK1 P23458 1/20 0.43
TYK2 P29597 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22853479 1.00 KDM4E (0.52) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL22853100 0.89 KDM4E (0.46) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL30294920 0.89 KDM4E (0.46) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL30294916 0.89 KDM4E (0.46) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL22852839 0.84 KDM4E (0.54) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL30294352 0.84 KDM4E (0.54) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL4511303 0.82 GAA (0.52) CTSVCTSLDHODHCYP2C19MAPT
SCHEMBL22853079 0.82 MPO (0.57) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL30294712 0.82 MPO (0.57) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL22853121 0.81 IDO1 (0.48) KDM4ECTSVCTSLDHODHMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B KDM4E 3392/4885APAF1 3972/4885RECQL 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.